Danielle Russell
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Danielle Russell has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Brendan Jacka
Kirby Institute UNSW Sydney Sydney Australia
2 shared publications - David Goodman-Meza
Kirby Institute, University of New South Wales, Sydney, Australia
2 shared publications - Marianne Martinello
The Kirby Institute, University of New South Wales, Sydney, Australia
2 shared publications - Alison D. Marshall
The Kirby Institute University of New South Wales Sydney New South Wales Australia
1 shared publication - Alison Ritter
Drug Policy Modelling Program, Social Policy Research Centre UNSW Sydney Sydney Australia
1 shared publication - Alys Havard
National Drug and Alcohol Research Centre, Faculty of Medicine and Health UNSW Sydney Sydney Australia
1 shared publication
Latest Publications
- Open Access
- 21 October 2026
- Published by Wiley in Drug and Alcohol Review
- Vol. 45 (7) , e70283
Recommendations to Enhance Engagement in Perinatal Research With People Who Inject Drugs
Women of reproductive age are significantly less likely than men to initiate hepatitis C virus (HCV) treatment, with the lowest uptake among women with children. Women who inject drugs who have children are a highly marginalised and stigmatised population who experience inequitable access to healthcare and poorer health outcomes. In the BUMP‐C qualitative study— Bridging Unified Management of Pregnancy in hepatitis C care —we sought to investigate current HCV care pathways and perceptions of HCV management during pregnancy among women who inject drugs. During this study, several lessons emerged from both the challenges and successes in engaging with this population. The aim of this commentary is to outline key recommendations for optimally engaging women who inject drugs in perinatal research. These recommendations include building trust with research participants, promoting strategies for research flexibility and seeking and valuing community and lived experience. The voices of women who inject drugs, often neglected in this space, must be prioritised to improve health outcomes for them and their children.
- 21 October 2026
- Published by Wiley in Drug and Alcohol Review
- Vol. 45 (7) , e70283
Open AccessRecommendations to Enhance Engagement in Perinatal Research With People Who Inject Drugs
Women of reproductive age are significantly less likely than men to initiate hepatitis C virus (HCV) treatment, with the lowest uptake among women with children. Women who inject drugs who have children are a highly marginalised and stigmatised population who experience inequitable access to healthcare and poorer health outcomes. In the BUMP‐C qualitative study— Bridging Unified Management of Pregnancy in hepatitis C care —we sought to investigate current HCV care pathways and perceptions of HCV management during pregnancy among women who inject drugs. During this study, several lessons emerged from both the challenges and successes in engaging with this population. The aim of this commentary is to outline key recommendations for optimally engaging women who inject drugs in perinatal research. These recommendations include building trust with research participants, promoting strategies for research flexibility and seeking and valuing community and lived experience. The voices of women who inject drugs, often neglected in this space, must be prioritised to improve health outcomes for them and their children.
- Open Access
- 14 May 2026
- Published by Wiley in Drug and Alcohol Review
- Vol. 45 (4) , e70169
Large Language Models Accurately Identify People Who Inject Drugs From Infectious Diseases Discharge Summaries in an Australian Hospital
Introduction: People who inject drugs (PWID) face a high risk for serious infections, yet International Classification of Diseases (ICD) codes fail to identify this population. Large language models (LLM) offer a promising alternative by extracting information from unstructured clinical text. This study evaluated the diagnostic performance of off‐the‐shelf LLMs in identifying PWID and related attributes from hospital discharge summaries. Methods: In this cross‐sectional study, discharge summaries from the Infectious Diseases service at St Vincent's Public Hospital, Sydney, between 2018 and 2022 were reviewed. A single reviewer manually annotated each de‐identified summary for PWID status, drugs reported, injection recency and opioid agonist therapy. Eight LLMs (Gemma3, Llama 3.3, Mistral, Phi4, hippomistral, llama3‐med [8B and 70B] and OpenBioLLM) were compared using prevalence‐weighted average‐F1 scores. Diagnostic metrics with bootstrapped 95% confidence intervals were calculated for each annotated category. Results: Of 859 first admissions, manual review identified 149 (17.1%) PWID. ICD codes showed low sensitivity (≤ 0.32) but high specificity (≥ 0.97) for identifying PWID. The best‐performing model (Llama 3.3) achieved a prevalence‐weighted average‐F1 of 0.845 (0.733, 0.927). For injecting drug use, sensitivity was 0.819 (95% CI 0.753, 0.879) and specificity 0.999 (0.996, 1.00). Identification of heroin, methamphetamine, cannabis and methadone was near perfect (F1 > 0.973), while illicit prescription opioid and benzodiazepine use were identified less accurately (F1 = 0.400 and 0.606). Discussion and Conclusions: LLMs accurately identify PWID from discharge summaries, outperforming ICD codes. Challenges remain for certain substances, underscoring the need for task‐specific tuning, external validation and integration with structured data to enhance surveillance and interventions.
- 14 May 2026
- Published by Wiley in Drug and Alcohol Review
- Vol. 45 (4) , e70169
Open AccessLarge Language Models Accurately Identify People Who Inject Drugs From Infectious Diseases Discharge Summaries in an Australian Hospital
Introduction: People who inject drugs (PWID) face a high risk for serious infections, yet International Classification of Diseases (ICD) codes fail to identify this population. Large language models (LLM) offer a promising alternative by extracting information from unstructured clinical text. This study evaluated the diagnostic performance of off‐the‐shelf LLMs in identifying PWID and related attributes from hospital discharge summaries. Methods: In this cross‐sectional study, discharge summaries from the Infectious Diseases service at St Vincent's Public Hospital, Sydney, between 2018 and 2022 were reviewed. A single reviewer manually annotated each de‐identified summary for PWID status, drugs reported, injection recency and opioid agonist therapy. Eight LLMs (Gemma3, Llama 3.3, Mistral, Phi4, hippomistral, llama3‐med [8B and 70B] and OpenBioLLM) were compared using prevalence‐weighted average‐F1 scores. Diagnostic metrics with bootstrapped 95% confidence intervals were calculated for each annotated category. Results: Of 859 first admissions, manual review identified 149 (17.1%) PWID. ICD codes showed low sensitivity (≤ 0.32) but high specificity (≥ 0.97) for identifying PWID. The best‐performing model (Llama 3.3) achieved a prevalence‐weighted average‐F1 of 0.845 (0.733, 0.927). For injecting drug use, sensitivity was 0.819 (95% CI 0.753, 0.879) and specificity 0.999 (0.996, 1.00). Identification of heroin, methamphetamine, cannabis and methadone was near perfect (F1 > 0.973), while illicit prescription opioid and benzodiazepine use were identified less accurately (F1 = 0.400 and 0.606). Discussion and Conclusions: LLMs accurately identify PWID from discharge summaries, outperforming ICD codes. Challenges remain for certain substances, underscoring the need for task‐specific tuning, external validation and integration with structured data to enhance surveillance and interventions.
- Open Access
- 22 December 2025
- Published by Wiley in Drug and Alcohol Review
- Vol. 45 (1) , e70084
Navigating the Gap: An Examination of Funder Rhetoric and Reality Regarding Community‐Research Partnerships
Partnerships between researchers and consumers—specifically, people who use drugs in the context of our research co‐production—can significantly enhance the relevance and impact of research. Funders increasingly emphasise the value of community‐researcher collaborations, yet translating this commitment into effective practice remains challenging. This commentary draws from our experience in developing an application for a collaborative grant with the National Health and Medical Research Council (NHMRC) in Australia, focusing on issues that impact people who use drugs. We reflect on four key insights that emerged from the grant‐writing process: (i) expectations and resources, highlighting the gap between the expectations of funding bodies, the way resourcing is used in academic contexts and the resources required for meaningful community involvement; (ii) grant success metrics, examining the disconnect between funding criteria and the realities of co‐production; (iii) representation, addressing the challenges of ensuring equitable and authentic consumer participation; and (iv) sharing power, discussing how power dynamics between researchers and community members influence the research process. In conclusion, we propose that researchers must work with consumers to foster more equitable working relationships and ensure there are adequate resources to support meaningful collaborations. Funding bodies, in turn, need to reconsider success metrics and ensure that their processes are mindful of the practical requirements that are necessary to facilitate genuine, equitable partnerships between researchers and consumers.
- 22 December 2025
- Published by Wiley in Drug and Alcohol Review
- Vol. 45 (1) , e70084
Open AccessNavigating the Gap: An Examination of Funder Rhetoric and Reality Regarding Community‐Research Partnerships
Partnerships between researchers and consumers—specifically, people who use drugs in the context of our research co‐production—can significantly enhance the relevance and impact of research. Funders increasingly emphasise the value of community‐researcher collaborations, yet translating this commitment into effective practice remains challenging. This commentary draws from our experience in developing an application for a collaborative grant with the National Health and Medical Research Council (NHMRC) in Australia, focusing on issues that impact people who use drugs. We reflect on four key insights that emerged from the grant‐writing process: (i) expectations and resources, highlighting the gap between the expectations of funding bodies, the way resourcing is used in academic contexts and the resources required for meaningful community involvement; (ii) grant success metrics, examining the disconnect between funding criteria and the realities of co‐production; (iii) representation, addressing the challenges of ensuring equitable and authentic consumer participation; and (iv) sharing power, discussing how power dynamics between researchers and community members influence the research process. In conclusion, we propose that researchers must work with consumers to foster more equitable working relationships and ensure there are adequate resources to support meaningful collaborations. Funding bodies, in turn, need to reconsider success metrics and ensure that their processes are mindful of the practical requirements that are necessary to facilitate genuine, equitable partnerships between researchers and consumers.
- Open Access
- 28 April 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (5) , ofaf257
Incidence, Patient-Directed Discharge, Readmission, and Mortality Among People Hospitalized With Injecting-Related Infection: A Population-Based Linkage Study
Background: Despite increasing hospitalization for injecting-related infection, there has been limited large-scale evaluation of in-hospital and post-discharge outcomes. This study aimed to characterize population-level injecting-related infection hospitalization and correlates associated with patient-directed discharge, readmission, and all-cause mortality among persons who inject drugs with hepatitis C in New South Wales, Australia, between 2001 and 2022. Methods: Hepatitis C notifications in New South Wales were linked to data involving hospitalizations, opioid agonist treatment, incarceration, and death registration. Hospitalizations among people who inject drugs with injecting-related infections were identified by ICD-10 code algorithms. Incidence of patient-directed discharge, readmission, and mortality was calculated, and correlates associated with each outcome were assessed by extension of a Cox proportional hazards model for recurrent events. Results: In total, 18074 injecting-related infection hospitalizations were included among 9045 individuals, predominantly males (64%) with an average age of 41 years. The incidence was 47.2 per 100 person-years and increased over time. The proportion of hospitalizations ending in patient-directed discharge was 18% and was associated with stimulant use and incarceration, and lower in those with severe disease and opiate agonist therapy. The proportions of hospitalizations that were followed by 30-day and 1-year readmission were 25% and 61%, respectively, and had a strong association with patient-directed discharge. Mortality was 2% at 30 days and 15% at 1 year post-discharge. Conclusions: Patient-directed discharge was common among people admitted with injecting-related infections and was associated with readmission but not mortality. Person-centered models of care are necessary to address the health inequity experienced by people who inject drugs.
- 28 April 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (5) , ofaf257
Open AccessIncidence, Patient-Directed Discharge, Readmission, and Mortality Among People Hospitalized With Injecting-Related Infection: A Population-Based Linkage Study
Background: Despite increasing hospitalization for injecting-related infection, there has been limited large-scale evaluation of in-hospital and post-discharge outcomes. This study aimed to characterize population-level injecting-related infection hospitalization and correlates associated with patient-directed discharge, readmission, and all-cause mortality among persons who inject drugs with hepatitis C in New South Wales, Australia, between 2001 and 2022. Methods: Hepatitis C notifications in New South Wales were linked to data involving hospitalizations, opioid agonist treatment, incarceration, and death registration. Hospitalizations among people who inject drugs with injecting-related infections were identified by ICD-10 code algorithms. Incidence of patient-directed discharge, readmission, and mortality was calculated, and correlates associated with each outcome were assessed by extension of a Cox proportional hazards model for recurrent events. Results: In total, 18074 injecting-related infection hospitalizations were included among 9045 individuals, predominantly males (64%) with an average age of 41 years. The incidence was 47.2 per 100 person-years and increased over time. The proportion of hospitalizations ending in patient-directed discharge was 18% and was associated with stimulant use and incarceration, and lower in those with severe disease and opiate agonist therapy. The proportions of hospitalizations that were followed by 30-day and 1-year readmission were 25% and 61%, respectively, and had a strong association with patient-directed discharge. Mortality was 2% at 30 days and 15% at 1 year post-discharge. Conclusions: Patient-directed discharge was common among people admitted with injecting-related infections and was associated with readmission but not mortality. Person-centered models of care are necessary to address the health inequity experienced by people who inject drugs.
- Open Access
- 20 June 2023
- Published by Oxford University Press (OUP) in Health Affairs Scholar
- Vol. 1 (1) , qxad018
Recent modifications to the US methadone treatment system are a Band-Aid—not a solution—to the nation's broken opioid use disorder treatment system
For 5 decades, US federal regulations have segregated methadone treatment for opioid use disorder from the rest of the health care system, confining its availability to specialty treatment programs that are highly regulated. These regulations have led to severe shortages in the availability of methadone and grave underutilization of this lifesaving medication despite a worsening overdose crisis. In this commentary, we discuss current barriers to methadone in the US opioid treatment system and how recent changes to federal regulations fall short of the reforms needed to significantly expand access to this treatment. Instead, we propose the urgent need to expand methadone to mainstream health care settings by allowing for office-based prescribing and pharmacy dispensing of methadone, the norm in many other developed countries.
- 20 June 2023
- Published by Oxford University Press (OUP) in Health Affairs Scholar
- Vol. 1 (1) , qxad018
Open AccessRecent modifications to the US methadone treatment system are a Band-Aid—not a solution—to the nation's broken opioid use disorder treatment system
For 5 decades, US federal regulations have segregated methadone treatment for opioid use disorder from the rest of the health care system, confining its availability to specialty treatment programs that are highly regulated. These regulations have led to severe shortages in the availability of methadone and grave underutilization of this lifesaving medication despite a worsening overdose crisis. In this commentary, we discuss current barriers to methadone in the US opioid treatment system and how recent changes to federal regulations fall short of the reforms needed to significantly expand access to this treatment. Instead, we propose the urgent need to expand methadone to mainstream health care settings by allowing for office-based prescribing and pharmacy dispensing of methadone, the norm in many other developed countries.